DXCM · DexCom Inc. — CGM Leader Expanding Into OTC

Research Date: May 12, 2026 Market Cap: ~$23.5B Research Type: Phase 2 Formal — Fact-based draft with cross-verified public sources

Data Credibility & Verification Layer

This report does not use local fact sheets (DXCM has not been onboarded to the internal fact-sheet system). All financial data is sourced from:

Limitations:

• No FactSet / Bloomberg consensus estimates
• SEC 10-Q MD&A not directly accessed
• US CGM market share figures are third-party estimates (not officially disclosed)
• Stelo OTC product revenue not separately broken out

Key Takeaways

Thesis: DexCom is the technology leader in continuous glucose monitoring (CGM), holding ~35% global share and ~74% US share in the ~$15B CGM market. The company is at the intersection of three growth engines: (1) G7 15-Day sensor penetrating traditional insulin users, (2) Stelo OTC product opening a brand-new TAM of 200M+ non-insulin diabetics and wellness consumers, and (3) international reimbursement expansion (France, Canada). Q1 2026 revenue was $1.19B (+15% YoY), gross margin jumped from 57.5% to 63.5%, and margin guidance was raised. The stock has pulled back from its 2024 high of $160+ to $61, bringing the PE down to 26x -- back to a reasonable range.

Scenario Analysis (educational illustration only):

• Bear: $45 (fwd PE 18x -- Abbott Libre continues taking share + reimbursement pressure)
• Base: $80 (fwd PE 30x -- G7 + Stelo dual growth engines + gross margin expansion)
• Bull: $105 (fwd PE 38x -- Stelo annual revenue >$1B + international outperformance)

Key Risks:

1. Abbott FreeStyle Libre competition (56% global share, lower price)
2. GLP-1 drugs (Ozempic/Mounjaro) reducing the diabetic population
3. Payer pressure (CMS/insurers pushing down CGM reimbursement rates)
4. Stelo OTC adoption falling short (consumer willingness to self-pay is unproven)
5. Stock down >60% from highs (weak technicals)

Note: No position recommendations. See Disclaimer.

1. Business Overview

Product Matrix

Competitive Advantages

1. Accuracy leadership: G7 MARD (Mean Absolute Relative Difference) is the lowest in the industry
2. Ecosystem integration: Automated closed-loop integration with Tandem/Insulet insulin pumps (Abbott's ecosystem is weaker)
3. Stelo first-mover: First FDA-approved OTC CGM, opening non-insulin TAM
4. 15-Day wear time: G7 15-Day extends sensor replacement from 10 days to 15 days, lowering user costs

Competitive Landscape

Key market data:

• 2026 global CGM market ~$15.3B, CAGR 15.4% (2026-2031), reaching ~$31.4B by 2031
• DexCom US market share ~74% (insulin users), but Abbott leads globally
• CGM industry is in a dual-driver phase: insulin-user standardization + non-insulin-user penetration

2. Financial Deep Dive

8-Quarter Revenue Trend

FY2024 total: $4.03B; FY2025 total: $4.66B (+16%). Some quarterly figures cross-verified with third-party sources.

Key observations:

1. 2024 mid-year growth trough (+2%): Q2-Q3 2024 were the slowest quarters, triggering a stock selloff
2. Double-digit growth resumed from Q4 2024: Driven by G7 15-Day launch + international expansion
3. Gross margin jumped from 57.5% to 63.5%: G7 15-Day sensors have lower unit costs (15-day vs. 10-day replacement) + Malaysia capacity ramp
4. International revenue accelerating (Q1 2026 +26% YoY): France/Canada CGM reimbursement expansion
5. GAAP net income improving steadily: From $135M to $199.5M (+48% over 8 quarters)

FY2026 Guidance

Balance Sheet

Balance sheet is essentially neutral: $2.5B liquidity vs. $2.5B convertible notes = near-zero net debt. Asset-light operations with primary fixed assets being Mesa, AZ and Malaysia manufacturing facilities. Annual FCF of ~$800M-$1B makes the company fully self-funding with no financing needs.

Valuation Snapshot

Current Price = $61.35
Market Cap = $23.5B
Enterprise Value (EV) = ~$23.5B (net debt ~ 0)

TTM Data (Q2 2025 - Q1 2026):
  Revenue = ~$4.75B
  Net Income = ~$735M
  FCF = ~$900M

Multiples:
  Trailing PE = 26x
  Forward PE = ~22x (FY26 EPS estimate ~$2.80)
  PS (TTM) = 5.0x
  EV/EBITDA = ~16x
  FCF Yield = ~3.8%
  PEG = ~1.7

DXCM has derated from PE 60x+ at 2024 highs to 26x, near historical lows. For a 15%-growth / 63.5%-gross-margin / 3.8%-FCF-yield MedTech company, PE 26x provides a reasonable margin of safety. The key question: if Stelo OTC proves to have lasting demand, growth could re-accelerate to 20%+, warranting re-rating to PE 30-35x.

3. Growth Drivers & Catalysts

Catalyst 1: G7 15-Day penetration driving gross margin expansion Gross margin improved from 57.5% to 63.5% (+600bp YoY). The 15-Day sensor has lower unit costs, and every 100bp of gross margin improvement translates to ~$50M in incremental profit.

Catalyst 2: Stelo OTC opening non-insulin TAM Revenue exceeded $100M in first 12 months. First FDA-approved OTC CGM. Target market: 25M non-insulin Type 2 diabetics in the US alone + wellness consumers = $5-10B incremental TAM.

Catalyst 3: International reimbursement expansion (France/Canada) Q1 2026 international revenue grew +26% YoY (+17% organic), driven by new reimbursement coverage in France and Canada. International revenue could grow from $1.4B to $2B+ within 2-3 years.

Catalyst 4: Valuation recovery (PE 26x to 30-35x) Stock has crashed >60% from 2024 highs. PE compressed from 60x to 26x = oversold. If growth stabilizes at 15%+ and margins keep expanding, the market will reprice accordingly.

Catalyst 5: Automated closed-loop insulin pump ecosystem (Tandem/Insulet/Omnipod) DexCom G7 is the preferred CGM for Tandem/Insulet closed-loop systems. As pump penetration rises, G7 usage becomes more sticky.

4. Risk Analysis

Risk 1: Abbott FreeStyle Libre competition (highest risk) Abbott holds 56% global CGM share with 5M+ installed base. The Libre 3 Plus is ~30% cheaper than G7, and the accuracy gap is narrowing. Monitor: DexCom US share trends and Abbott CGM growth vs. DexCom.

Risk 2: GLP-1 drugs reducing CGM demand Ozempic/Mounjaro improve Type 2 diabetes blood sugar control, potentially reducing CGM need. Counter-argument: GLP-1 users also need CGM to monitor drug efficacy. Monitor: CGM new-user growth rate vs. GLP-1 prescription volumes.

Risk 3: Payer reimbursement pressure CMS Medicare CGM reimbursement rates face downward pressure. If CMS materially cuts CGM reimbursement, DexCom ASP could decline 10%+.

Risk 4: Stelo OTC adoption shortfall Consumer self-pay of ~$90/month ($1,080/year) raises long-term retention questions. If Stelo revenue stagnates at $100-200M, it fails to become a growth engine.

Risk 5: Weak technicals (-63% from highs) Stock fell from $164 in 2024 to $61, trading below 200-day MA. A break below $50 support could lead to further downside toward $40. However, improving fundamentals can reverse technical weakness.

5. Valuation Framework

Scenario Analysis (educational illustration only):

Peer Comparison

DexCom is the "premium brand + OTC pioneer" of the CGM space. In the US insulin-user market, DexCom maintains dominance via accuracy and closed-loop ecosystem. Globally, Abbott leads on price and coverage. Stelo OTC is the sole differentiating strategic variable -- success expands the TAM 3-5x; failure confines DexCom to a narrower addressable market.

Tracking Metrics (Next 4 Quarters)

This report is for educational purposes only and does not constitute investment advice. All data sourced from SEC EDGAR filings and public company disclosures. See full Disclaimer.